Literature DB >> 8988055

Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.

M Okamoto1, C Lee, R Oyasu.   

Abstract

Interleukin (IL)-6 plays a significant role in genitourinary carcinomas. The present study was conducted to define the role of IL-6 in the growth of prostatic carcinoma and benign prostatic hyperplasia (BPH). An in vitro experiment was carried out using human prostatic carcinoma cell lines (LNCaP, which is androgen sensitive and slow growing, and DU145 and PC3, which are androgen insensitive and fast growing), and primary human epithelial and stromal cells derived from BPH. Cells were treated with recombinant human IL-6 or conditioned medium (CM) derived from the above cultured cells to identify possible paracrine and autocrine pathways. LNCaP was clearly responsive to exogenous IL-6 and to the CM derived from stromal cells, but not to the CM from LNCaP cells (P < 0.001). DU145 and PC3 were slightly stimulated to grow by exogenous IL-6 and the CM derived from both stromal and respective homologous cells (P < 0.01). In contrast, BPH-derived epithelial cells showed little or no response to IL-6. The stimulatory effect of CM on prostatic carcinoma cells was significantly reduced by the addition of anti-IL-6 antibody to the culture medium. Furthermore, the growth of DU145 and PC3 in serum-free medium was also inhibited by anti-IL-6 antibody (P < 0.001). All cell lines tested, except for LNCaP, secreted IL-6 into the culture medium. Results of reverse transcriptase-PCR analysis indicated that IL-6 receptor mRNA was present in all carcinoma cell lines but not in epithelial cells or stromal cells derived from BPH. These results suggest that IL-6 functions as a paracrine growth factor for LNCaP and as an autocrine growth factor for DU145 and PC3, but it has no stimulatory effect on epithelial cells derived from BPH.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8988055

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  77 in total

Review 1.  BCG response prediction with cytokine gene variants and bladder cancer: where we are?

Authors:  Dinesh Kumar Ahirwar; Parmeet Kaur Manchanda; Rama Devi Mittal; Hemant K Bid
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-20       Impact factor: 4.553

2.  IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells.

Authors:  Chih-Hsin Tang; Cheng-Fong Chen; Wei-Ming Chen; Yi-Chin Fong
Journal:  J Biol Chem       Date:  2011-01-28       Impact factor: 5.157

3.  Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation.

Authors:  Uddalak Bharadwaj; Christian Marin-Muller; Min Li; Changyi Chen; Qizhi Yao
Journal:  Carcinogenesis       Date:  2011-04-23       Impact factor: 4.944

4.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.

Authors:  Christopher Johnson; Yuyan Han; Nathan Hughart; Jennifer McCarra; Gianfranco Alpini; Fanyin Meng
Journal:  Transl Gastrointest Cancer       Date:  2012-04-01

5.  The picture of the prostatic lymphokine network is becoming increasingly complex.

Authors:  Georg E Steiner; Bob Djavan; Gero Kramer; Alessandra Handisurya; Martin Newman; Chung Lee; Michael Marberger
Journal:  Rev Urol       Date:  2002

6.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

Review 7.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

8.  The effect of interleukin-6 on the proliferation of prostate cancer cells in vitro and the modulation of this procedure.

Authors:  Y Xing; Y Xiao; Q Zhang; G Lu
Journal:  J Tongji Med Univ       Date:  2001

Review 9.  Molecular mechanisms of castration-resistant prostate cancer progression.

Authors:  Smitha S Dutt; Allen C Gao
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

10.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.